Tebentafusp innovatively combines TCR targeting tumor antigens with immune-effect domains that bind to CD3 subjects.
designed to guide and activate T-cells, allowing them to identify and kill cancer cells.
Tebentafusp specific target gp100, an antigen expressed in melanin cells and melanoma.
noteworthy is that the company's technology allows TCR to identify cancer antigens in cells with high affinity, which is expected to break through the limitations of existing antibody drugs and increase the number of identifiable targets from 10 percent to 90 percent.
In addition, based on existing mechanisms for T-cell immersion of human tumors, Immunocore also points out that its TCR technology is expected to be used to treat immunologically "cold tumors", tumors with low mutation rates that have traditionally been difficult to attract the attention of the immune system.
breakthrough therapy is based on phase 3 clinical trial results published in November 2020.
-term analysis showed that tebentafusp showed significant survival benefits in treating patients with primary metastasis melanoma compared to other therapies chosen by the researchers, including dacarbazine, ipilimumab, or pembrolizumab.
although the data are not yet fully mature, the tebentafusp group currently has a one-year survival rate of 73%, better than the other treatment groups of 58%.
: This article is intended to introduce medical and health research, not treatment options recommended.
if you need guidance on treatment options, visit a regular hospital.
resources: s tebentafusp granted ByRessInse reserved The Therapy Designation for unresectable or metastatic uveal melanoma from FDA. Retrieved February 19, 2021, from  Bertil E. Damato et al., (2019), Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma, Cancers, DOI: